Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET: Triple Therapy vs TNF Inhibitors in RA
NCT02374021Phase 4Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Jul 2016
- Primary completion
- May 2021
- Modality
- Small Molecules, Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of etanercept, adalimumab, 5-aminosalicylic acid + sulphasalazine and hydroxychloroquine in rheumatoid arthritis (RA) (2 arms), sponsored by Brigham and Women's Hospital. Primary endpoint: Change From Baseline in Vascular Inflammation as Measured by FDG-PET/CT at 6 months. Started Jul 2016; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02374021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02374021.